693 results on '"Riemekasten, G"'
Search Results
2. POS0211 PAH TREATMENT AT TIME OF DIAGNOSIS IS ASSOCIATED WITH IMPROVED SURVIVAL REGARDLESS OF HEMODYNAMIC THRESHOLDS AND RISK STRATIFICATION - A EUSTAR ANALYSIS
3. AB1196 BASELINE DEMOGRAPHICS AND DISEASE CHARACTERISTICS IN SUBJECTS WITH ILD IN A PHASE 2 STUDY TO EVALUATE EFFICACY, SAFETY, AND TOLERABILITY OF MT-7117 IN DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS
4. POS0832 IMMUNOSUPPRESSION VERSUS COMBINATION OF IMMUNOSUPPRESSION AND ORAL GLUCOCORTICOIDS FOR SKIN FIBROSIS IN EARLY DIFFUSE SYSTEMIC SCLEROSIS PATIENTS. A TARGET TRIAL EMULATION STUDY FROM THE EUSTAR DATABASE
5. OP0013 ANTI-Ro/SSA ANTIBODIES ARE PREDICTIVE OF A MORE SEVERE LUNG INVOLVEMENT IN PATIENTS WITH SYSTEMIC SCLEROSIS: A STUDY FROM THE EUSTAR HDATABASE
6. Versorgungsrealität der stationären vasoaktiven Therapie mit Prostazyklinderivaten bei Patienten mit akralen Durchblutungsstörungen bei systemischer Sklerose in Deutschland
7. Serum Levels of Autoantibodies Against Extracellular Antigens and Neutrophil Granule Proteins Increase in Patients with COPD Compared to Non-COPD Smokers
8. Cohort Enrichment Strategies for Progressive Interstitial Lung Disease in Systemic Sclerosis From European Scleroderma Trials and Research
9. Systemische Sklerose: Teil 1: Diagnose und Organmanifestationen
10. Imitatoren der systemischen Sklerose
11. AB0919 DYNAMIC OPTICAL COHERENCE TOMOGRAPHY MIGHT BE A VALUABLE TOOL TO ASSESS THERAPEUTIC EFFICACY OF VASOACTIVE THERAPY IN SYSTEMIC SCLEROSIS
12. OP0238 IMMUNOSUPPRESSION WITH TARGETED DMARDS REDUCES MORBIDITY AND MORTALITY IN PRE-CAPILLARY PULMONARY HYPERTENSION ASSOCIATED WITH SYSTEMIC SCLEROSIS: A EUSTAR ANALYSIS
13. POS0150 AUTOANTIBODIES AGAINST FIBROBLAST GROWTH FACTOR (FGF-2), PLACENTAL GROWTH FACTOR (PLGF) AND BETA-ADRENERGIC RECEPTOR 1 (ADRB1) IN AN ALTERED NETWORK OF AUTOANTIBODIES IN SYSTEMIC SCLEROSIS
14. POS0875 AUTOANTIBODIES DIRECTED TO G-PROTEIN COUPLED RECEPTORS CORRELATE WITH DISEASE ACTIVITY SCORES IN PATIENTS WITH PSORIATIC ARTHRITIS
15. POS0121 COMPARISON OF FOUR RISK STRATIFICATION MODELS FOR PREDICTION OF MORTALITY IN SSc-PAH IN THE EUSTAR COHORT
16. AB0157 SYNERGISTIC EFFECT OF AT1R-AUTOANTIBODIES AND EXTRACELLULAR VESICLES IN SSC PATHOGENESIS
17. POS1161 RITUXIMAB VS. COMBINATION OF RITUXIMAB AND CYCLOPHOSPHAMIDE INDUCTION THERAPY FOR ANCA-ASSOCIATED VASCULITIS: A RETROSPECTIVE STUDY
18. The first composite score predicting Digital Ulcers in systemic sclerosis patients using Clinical data, Imaging and Patient history—CIP-DUS
19. Classification, categorization and essential items for digital ulcer evaluation in systemic sclerosis: a DeSScipher/European Scleroderma Trials and Research group (EUSTAR) survey
20. Fighting Post-COVID and ME/CFS – development of curative therapies
21. Effects of a personalized interprofessional multimodal rheumatologic complex intervention in 109 patients: A monocentric prospective study
22. Angiotensin II type I receptor (AT1R) antibodies induce structural changes of the glycocalyx of human umbilical vein endothelial cells
23. Recovery of regulatory T cells by in vitro stimulation with low doses of interleukin-2 in patients with myositis
24. Rituximab vs. combination of Rituximab and Cyclophosphamide induction therapy for ANCA-associated vasculitis: A retrospective study
25. Ausprägung der gastrointestinalen Beteiligung der Systemischen Sklerose im Erkrankungsverlauf
26. Impact of systemic sclerosis-associated interstitial lung disease with and without pulmonary hypertension on survival in over 5,000 patients
27. Association between baseline clinical and imaging findings and the development of digital ulcers in patients with systemic sclerosis
28. Digitale Ulzerationen bei systemischer Sklerose: Eine Versorgungsforschungsstudie über den Einsatz von Bosentan und anderen vasoaktiven Therapien
29. Interstitial lung disease increases mortality in systemic sclerosis patients with pulmonary arterial hypertension without affecting hemodynamics and exercise capacity
30. Therapiedeeskalation bei ANCA-assoziierten Vaskulitiden
31. Stratification in systemic sclerosis according to autoantibody status versus skin involvement: a study of the prospective EUSTAR cohort
32. S11.3 Low-dose interleukin-2 therapy in active systemic lupus erythematosus (lupil-2): a multi-center, double-blind, randomized and placebo-controlled phase 2 trial
33. Therapy satisfaction and health literacy are key factors to improve medication adherence in systemic sclerosis
34. Cohort enrichment strategies for progressive interstitial lung disease in systemic sclerosis from EUSTAR
35. Progressive interstitial lung disease is frequent also in late disease stages in systemic sclerosis patients from EUSTAR
36. Risk stratification approaches perform differently in SSc-associated PAH in EUSTAR
37. ACE inhibitors in SSc patients display a risk factor for scleroderma renal crisis—a EUSTAR analysis
38. Therapy satisfaction and health literacy are key factors to improve medication adherence in systemic sclerosis.
39. Rheumatologie – Integration in die studentische Ausbildung (RISA): Zur aktuellen Struktur der internistischen Rheumatologie an deutschen Hochschulen (RISA III)
40. Europäische Versorgungsstandards für Menschen mit rheumatoider Arthritis: Übersetzung und Kommentierung der von der EULAR unterstützten Vorschläge des eumusc.net durch eine Task Force von DGRh und VRA mit Unterstützung der Deutschen Rheuma-Liga
41. Erfolgsmodell Studentenprogramm: Rückblick auf den DGRh-Kongress 2015
42. POS0140 PREDICTING OUTCOMES IN SYSTEMIC SCLEROSIS: STRATIFICATION BY AUTO-ANTIBODIES OUTPERFORMS CUTANEOUS SUBSETTING IN THE EUSTAR COHORT
43. POS0914 LATE SKIN FIBROSIS IN SYSTEMIC SCLEROSIS: A STUDY FROM THE EUSTAR COHORT
44. AB0028 IL-2 DEPRIVED PHENOTYPE OF FOXP3+ REGULATORY T CELLS AND PHENOTYPIC ALTERATIONS CONVENTIONAL CD4+ T CELLS IN PATIENTS WITH INFLAMMATORY MYOPATHIES AND PRIMARY SJOGREN´S SYNDROME
45. AB0137 SERA DERIVED EXTRACELLULAR VESICLES FROM SYTEMIC SCLEROSIS PATIENT AND AUTOANTIBODIES MEDIATE PERIPHAL BLOOD MONOCYTES ACTIVATION
46. POS0829 SPECTRUM OF ANCA-SPECIFICITIES IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS IN A RETROSPECTIVE MULTICENTER STUDY
47. POS0387 RISK STRATIFICATION APPROACHES PERFORM DIFFERENTLY IN SSc-ASSOCIATED PAH IN EUSTAR
48. AB0660 Long-term effect of combination therapy with rituximab and mycophenolic acid on cardiac manifestations, pulmonary function and skin fibrosis in systemic sclerosis
49. POS1287 INFLUENCES ON FIBROMYALGIA AND AUTOANTIBODIES DIRECTED TO NEURO- AND VASOREGULATORY MOLECULES NEED TO BE CONSIDERED IN BIOMARKER RESEARCH
50. POS0854 BASELINE CHARACTERISTICS OF PATIENTS WITH IMPROVEMENT OR PROGRESSION OF SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSc-ILD) DURING THE SENSCIS TRIAL
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.